Client News

[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: August 29, 2014, 5:19 pm
Posted: August 29, 2014, 3:53 pm
[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 29, 2014 /PR Newswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing of ...
Posted: August 29, 2014, 12:00 pm
Posted: August 29, 2014, 6:16 am
Posted: August 28, 2014, 10:02 pm
Posted: August 28, 2014, 5:19 pm
Posted: August 28, 2014, 5:04 pm
[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Tuesday, September 9th at 2:55 p.m. EDT in the Kennedy II Salon (4th floor) at the New York Palace Hotel in New York City. Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's progress in developing important, new chemotherapies for patients who have little to no therapeutic options. DelMar's lead drug, VAL-083, is currently undergoing human clinical trials as a potential new chemotherapy to treat refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Posted: August 27, 2014, 6:57 pm
Posted: August 27, 2014, 1:58 pm
[GlobeNewswire] - RUTHERFORD, N.J. -- Cancer Genetics, Inc. ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today that the National Institutes of Health's (NIH) ...
Posted: August 27, 2014, 11:59 am
[PR Newswire] - SAN DIEGO, Aug. 27, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory ...
Posted: August 27, 2014, 11:30 am
Posted: August 27, 2014, 10:23 am
[Thomson Reuters ONE] - Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson`s Disease Results Extend Prior Research Confirming Skin Response (Goose Bump) Deficit ...
Posted: August 26, 2014, 8:07 pm
[GlobeNewswire] - DUBLIN, Ireland -- Prothena Corporation plc , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases ...
Posted: August 26, 2014, 8:05 pm
Posted: August 26, 2014, 5:04 pm